Integrated Analysis Reveals ZNF184 as a Novel Regulator of Stemness‐Associated Paclitaxel Resistance and Tumor Progression in Breast Cancer
Molecular Carcinogenesis · 2026
DOI: 10.1002/mc.70088 ↗At a glance
Journal article in Molecular Carcinogenesis, 2026. Written by Rong Gong and 9 co-authors. Institution: Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China. Major MEDLINE topics: Paclitaxel, Drug Resistance, Neoplasm, Breast Neoplasms, Neoplastic Stem Cells. 25 references. Funded by: National Natural Science Foundation of China, Changsha Science and Technology Project.
Abstract (original language)
Chemotherapy resistance is the primary cause of clinical treatment failure and unfavorable prognosis among breast cancer patients. Consequently, the exploration of novel molecular targets for chemotherapy resistance is warranted. Here, we demonstrated that Zinc Finger Protein 184 (ZNF184) facilitates chemoresistance in breast cancer. Through integrated bioinformatics and experimental validation, we identified that ZNF184 was highly expressed in paclitaxel‐resistant breast cancer cells. Knockdown of ZNF184 inhibited cell proliferation and re‐sensitized resistant cells to paclitaxel in vitro and in patients‐derived organoids (PDOs). Mechanistically, ZNF184 regulates the expression of stemness‐related genes CD44, OCT4, Nanog, SOX2, and ALDH1A1, thereby promoting the proliferation of breast cancer cells and subsequent paclitaxel resistance. Pan‐cancer analysis revealed the potential of ZNF184 as a prognostic and predictive biomarker for adverse clinical outcomes. Collectively, these findings reveal a previously unknown role of ZNF184 in breast cancer progression and paclitaxel resistance, providing new insights into ZNF184 as a potential therapeutic target for cancer patients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
- Hunan Provincial Engineering Research Center of Translational Medicine and Innovative Drug, Changsha, China.
- Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
- Zhuzhou Nanfang High School, Zhuzhou, China.
- Department of Pathology, Xiangya Hospital, Central South University, Changsha, China.
- Information and Network Center, Central South University, Changsha, China.
ORCID profiles: Yan Cheng
Funding
- National Natural Science Foundation of China
- Changsha Science and Technology Project
Cite
APA
Gong, R., Li, Y., Wan, X., Jiang, S., Wang, D., Fu, Q., Yang, A., Guan, Y., Zhao, R., & Cheng, Y. (2026). Integrated Analysis Reveals ZNF184 as a Novel Regulator of Stemness‐Associated Paclitaxel Resistance and Tumor Progression in Breast Cancer. Molecular Carcinogenesis. https://doi.org/10.1002/mc.70088
Vancouver
Gong R, Li Y, Wan X, Jiang S, Wang D, Fu Q, et al. Integrated Analysis Reveals ZNF184 as a Novel Regulator of Stemness‐Associated Paclitaxel Resistance and Tumor Progression in Breast Cancer. Molecular Carcinogenesis. 2026. doi:10.1002/mc.70088
BibTeX
@article{Gong2026,
author = {Gong, Rong and Li, Yizhi and Wan, Xiaoya and Jiang, Shilong and Wang, Deyang and Fu, Qi and Yang, Anze and Guan, Yidi and Zhao, Ruigang and Cheng, Yan},
title = {Integrated Analysis Reveals ZNF184 as a Novel Regulator of Stemness‐Associated Paclitaxel Resistance and Tumor Progression in Breast Cancer},
journal = {Molecular Carcinogenesis},
year = {2026},
doi = {10.1002/mc.70088}
}
EUVIMED